MedTrace Logo

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

NCT02681978 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-02-15

No results posted yet for this study

Summary

This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.

Conditions

Interventions

DRUG

Ivabradine

Ivabradine 5 mg twice daily

DRUG

Standard medical therapy

Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Sponsors & Collaborators

  • Campus Bio-Medico University

    lead OTHER

Principal Investigators

  • Fabio Mangiacapra, MD, PhD · Campus Bio-Medico University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02681978 on ClinicalTrials.gov